Journal article
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, TA Chan, G Coukos, S Demaria, E Deutsch, D Draganov, RL Edelson, SC Formenti, J Fucikova, L Gabriele, US Gaipl, SR Gameiro, AD Garg, E Golden, J Han Show all
Journal for Immunotherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2020
Open access
Abstract
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
Grants
Awarded by U.S. Department of Defense
Funding Acknowledgements
LG is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine, by industrial collaborations with Lytix and Phosplatin, and by donations from Sotio a.s., Phosplatin, and the Luke Heller TECPR2 Foundation. IV is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017 grant number 20417) and a startup grant from the Italian Institute for Genomic Medicine (Candiolo, Turin, Italy) and Compagnia di San Paolo (Turin, Italy).